IAVI awarded $36 million from BARDA for Bundibugyo virus vaccine development
On Oct. 28, 2026, IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience,…
-
-
Biotechnology | NIH | Vaccine
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS®, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
On Sept. 2, 2025, Emergent BioSolutions announced it had received a $30 million contract modification from the Biomedical Advanced…
-
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
On Aug. 26, 2025, Osivax announced it has secured $19.5 million in funding from the Biomedical Advanced Research…
-
Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay
On Feb. 18, 2025, Hologic announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance…
-
U.S. awarded Moderna $590 million for bird flu vaccine development
On Jan. 17, 2025, The U.S. government announced it had awarded Moderna $590 million to advance the development…
-
BARDA Awards $375 million to develop COVID-19 pre-exposure prophylaxis
On Jan. 16, 2025, Shionogi Inc. has been awarded a $375 million project agreement through the Rapid Response…
-
Biotechnology | Chemistry | FDA | NIH | Radiology | Therapeutics
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
On Oct. 28, 2024, HOPO Therapeutics announced that it has been awarded a contract valued at up to…
-
RedHill Biopharma Secured U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
On Oct. 14, 2024, RedHill Biopharma announced that the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA)…
-
Sabin Vaccine Institute Sent Additional Vaccines to Rwanda for Marburg Outbreak
On Oct. 12, 2024, the Sabin Vaccine Institute announced it had delivered approximately 1,000 more investigational vaccine doses…
-
Moderna Received $176 million Award through BARDA to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
On Jul. 2, 2024, Moderna announced a project award of $176 million through the Rapid Response Partnership Vehicle…
-
Emergent received $75 million contract option from BARDA to procure doses of CYFENDUS (Anthrax Vaccine)
On Nov. 28, 2023, Emergent BioSolutions announced that the Biomedical Advanced Research and Development Authority (BARDA) within the…
-
Vir Biotechnology awarded BARDA funding to support development of antibody platform technologies for global infectious disease threats
On Oct. 3, 2023, Vir Biotechnology announced that the Biomedical Advanced Research and Development Authority (BARDA), part of…
-
Gritstone Bio awarded $433 Mmillion BARDA contract to conduct comparative phase 2b study evaluating next-generation vaccine candidate for COVID-19
On Sept. 27, 2023, Gritstone bio announced that it was awarded a contract by the Biomedical Advanced Research…
-
Emergent BioSolutions awarded 10-Year BARDA contract valued at $704 million for Ebanga treatment for Ebola
On Jul. 31, 2023, Emergent BioSolutions announced that it was awarded a 10-year contract by the Biomedical Advanced…
-
Texas Biomed added to national readiness and preparedness network
On Dec. 13, 2022, Texas Biomed announced that it had been designated as a prime contractor by the…
-
Hologic announced contract with BARDA to support IVD approval of COVID assays
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
-
U.S. Department of Health and Human Services funded U.S.-based production of Smallpox and Mpox vaccine
On Aug. 29, 2022, the U.S. Department of Health and Human Services (HHS) announced it had provided approximately…
-
Immune modulator drugs improved survival for people hospitalized with COVID-19
On Jun. 2, 2022, the U.S. National Institutes of Health (NIH) announced that a large randomized, placebo-controlled clinical…
-
OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver
On Sept. 23, 2021, OraSure Technologies and the Biomedical Advanced Research Development Authority (BARDA) announced up to $13.6…
-
Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)
On Jun. 29, 2021, Paratek Pharmaceuticals announced it has delivered the first procurement of NUZYRA to the Biomedical…
-
U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
HHS launched first venture capital partnership to develop transformative technologies to combat future pandemics
On Jun. 1, 2021, the U.S. Department of Health and Human Services (HHS) unveiled a new type of…
-
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
-
Moderna announced participants dosed in phase 2/3 study of COVID-19 vaccine in pediatric population
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
-
ContraFect announced BARDA contract award for up to $868 million for antibiotic-resistant infections
On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced…
-
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
-
Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
-
Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
-
INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…
-
Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescents
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
